Chayab, L.; Leighl, N.B.; Tadrous, M.; Warren, C.M.; Wong, W.W.L.
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Curr. Oncol. 2025, 32, 13.
https://doi.org/10.3390/curroncol32010013
AMA Style
Chayab L, Leighl NB, Tadrous M, Warren CM, Wong WWL.
Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Current Oncology. 2025; 32(1):13.
https://doi.org/10.3390/curroncol32010013
Chicago/Turabian Style
Chayab, Lara, Natasha B. Leighl, Mina Tadrous, Christine M. Warren, and William W. L. Wong.
2025. "Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada" Current Oncology 32, no. 1: 13.
https://doi.org/10.3390/curroncol32010013
APA Style
Chayab, L., Leighl, N. B., Tadrous, M., Warren, C. M., & Wong, W. W. L.
(2025). Trends in Real-World Clinical Outcomes of Patients with Anaplastic Lymphoma Kinase (ALK) Rearranged Non-Small Cell Lung Cancer (NSCLC) Receiving One or More ALK Tyrosine Kinase Inhibitors (TKIs): A Cohort Study in Ontario, Canada. Current Oncology, 32(1), 13.
https://doi.org/10.3390/curroncol32010013
